Novo Nordisk study shows cost-effectiveness of Victoza

Novo Nordisk has announced data from a new study showing the cost-effectiveness benefits of Victoza, its type 2 diabetes therapy.

Findings from a health economics and outcomes research analysis demonstrated that Victoza 1.2 mg is more cost-effective for the treatment of type 2 diabetes in the UK market when compared to one established therapy and is cost-saving compared to another.

The analysis was based on changes seen in blood glucose level, blood pressure and body mass index on initiation of each treatment, taken from a network meta-analysis of 13 randomised controlled trials.

Dr Klaus Henning Jensen, head of clinical, medical and regulatory affairs at Novo Nordisk in the UK and Ireland, said: "As the population with type 2 diabetes increases, it is vital that cost-effective medications such as liraglutide are available to help improve patients' quality of life and prevent complications."

Victoza was launched in the EU in 2009 and is now commercially available in more than 80 countries with more than three million patient years of use in people with type 2 diabetes globally.